Structure−Activity Study To Develop Cationic Lipid-Conjugated Haloperidol Derivatives as a New Class of Anticancer Therapeutics
摘要:
Haloperidol (HP), a neuroleptic drug, shows high affinity toward sigma receptors (SR). HP and reduced-HP at higher concentration were known to induce apoptosis in SR-overexpressing carcinomas and melanomas. Herein, we report the development of cationic lipid-conjugated haloperidol as a new class of anticancer therapeutics. In comparison to HP, the C-8 carbon chain analogue (HP-C8) showed significantly high, SR-assisted antiproliferative activity against cancer cells via caspase-3-mediated apoptosis and down-regulation of pAkt. Moreover, melanoma tumor aggressiveness in HP-C8-treated mice was significantly lower than that in HP-treated mice. HP-C8 simultaneously reduced Akt-protein level and increased Bax/Bcl-2 ratio in vascular endothelial cells, thereby indicating a possible protein kinase down-regulatory and apoptosis inducing role in tumor-associated vascular cells. In conclusion, we developed sigma receptor-targeting cationic lipid-modified HP derivatives as a promising class of anticancer therapeutic that concurrently affects cancer and tumor environment associated angiogenic vascular cells through induction of apoptosis and Akt protein down-regulation.
[EN] A NANOFORMULATION FOR GLIOMA TREATMENT AND PROCESS FOR ITS PREPARATION THEREOF [FR] NANOFORMULATION DESTINÉE AU TRAITEMENT DE GLIOMES ET SON PROCÉDÉ DE PRÉPARATION
摘要:
The present invention describes the development of a novel, tumor epithelial cell and tumor-associated macrophage (TAM)-targeting, blood brain barrier (BBB) crossing glucose-based nanospheres (CSP). More specifically, the present invention discloses a nanoformulation and/or a composition having anticancer activity comprising of carbon nanosphere (CSP) and a sigma receptor targeting ligand (H8) in the ratio of 1: 0.08 to 1: 0.2, a complex prepared thereof, a process for preparation thereof and a kit for delivery of the drug molecule or the formulation or the composition to tumor site.
Haloperidol (HP), a neuroleptic drug, shows high affinity toward sigma receptors (SR). HP and reduced-HP at higher concentration were known to induce apoptosis in SR-overexpressing carcinomas and melanomas. Herein, we report the development of cationic lipid-conjugated haloperidol as a new class of anticancer therapeutics. In comparison to HP, the C-8 carbon chain analogue (HP-C8) showed significantly high, SR-assisted antiproliferative activity against cancer cells via caspase-3-mediated apoptosis and down-regulation of pAkt. Moreover, melanoma tumor aggressiveness in HP-C8-treated mice was significantly lower than that in HP-treated mice. HP-C8 simultaneously reduced Akt-protein level and increased Bax/Bcl-2 ratio in vascular endothelial cells, thereby indicating a possible protein kinase down-regulatory and apoptosis inducing role in tumor-associated vascular cells. In conclusion, we developed sigma receptor-targeting cationic lipid-modified HP derivatives as a promising class of anticancer therapeutic that concurrently affects cancer and tumor environment associated angiogenic vascular cells through induction of apoptosis and Akt protein down-regulation.
[EN] A NANOFORMULATION FOR GLIOMA TREATMENT AND PROCESS FOR ITS PREPARATION THEREOF<br/>[FR] NANOFORMULATION DESTINÉE AU TRAITEMENT DE GLIOMES ET SON PROCÉDÉ DE PRÉPARATION
申请人:[en]COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
公开号:WO2022208546A1
公开(公告)日:2022-10-06
The present invention describes the development of a novel, tumor epithelial cell and tumor-associated macrophage (TAM)-targeting, blood brain barrier (BBB) crossing glucose-based nanospheres (CSP). More specifically, the present invention discloses a nanoformulation and/or a composition having anticancer activity comprising of carbon nanosphere (CSP) and a sigma receptor targeting ligand (H8) in the ratio of 1: 0.08 to 1: 0.2, a complex prepared thereof, a process for preparation thereof and a kit for delivery of the drug molecule or the formulation or the composition to tumor site.